Arcturus Therapeutics Holdings, Inc.

How big is Arcturus Therapeutics Holdings, Inc.?

As of Jun 18, Arcturus Therapeutics Holdings, Inc. has a market capitalization of 333.04 million and reported net sales of 131.28 million with a net profit of -68.21 million over the latest four quarters. Shareholder's funds were 240.98 million, and total assets were 344.07 million.

As of Jun 18, Arcturus Therapeutics Holdings, Inc. has a market capitalization of 333.04 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 131.28 million for the latest four quarters. During the same period, it recorded a net profit of -68.21 million.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 240.98 million, while total assets were reported at 344.07 million.

What does Arcturus Therapeutics Holdings, Inc. do?

Arcturus Therapeutics Holdings, Inc. is a clinical-stage company focused on mRNA medicines and vaccines in the Pharmaceuticals & Biotechnology industry, with a market cap of $333.04 million. As of March 2025, it reported net sales of $25 million and a net loss of $14 million.

Overview: <BR>Arcturus Therapeutics Holdings, Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company operating in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 25 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 333.04 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -5.41% <BR>Price to Book: 1.42<BR><BR>Contact Details: <BR>Address: 10628 Science Center Dr Ste 250, SAN DIEGO CA: 92121-1132 <BR>Tel: 1 858 9002660 <BR>Website: https://arcturusrx.com/

Who are in the management team of Arcturus Therapeutics Holdings, Inc.?

As of March 2022, the management team of Arcturus Therapeutics includes Dr. Peter Farrell (Independent Chairman), Mr. Joseph Payne (CEO), Mr. Andrew Sassine (CFO), and several independent directors: Ms. Karah Parschauer, Mr. James Barlow, Dr. Edward Holmes, and Dr. Magda Marquet. This team combines executive leadership with independent oversight for diverse governance.

As of March 2022, the management team of Arcturus Therapeutics Holdings, Inc. includes the following individuals:<BR><BR>- Dr. Peter Farrell, who serves as the Independent Chairman of the Board.<BR>- Mr. Joseph Payne, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Andrew Sassine, who holds the position of Chief Financial Officer and is also a Director.<BR>- Ms. Karah Parschauer, who is a Director.<BR>- Mr. James Barlow, who is an Independent Director.<BR>- Dr. Edward Holmes, who is an Independent Director.<BR>- Dr. Magda Marquet, who is also an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, providing a diverse governance structure for the company.

Should I buy, sell or hold Arcturus Therapeutics Holdings, Inc.?

Is Arcturus Therapeutics Holdings, Inc. overvalued or undervalued?

As of March 7, 2024, Arcturus Therapeutics Holdings, Inc. is considered overvalued and risky due to negative earnings, a -5.41% ROE, and poor long-term performance, despite a recent short-term gain of 8.76%.

As of 7 March 2024, the valuation grade for Arcturus Therapeutics Holdings, Inc. has moved from fair to risky, indicating a more cautious outlook. The company appears to be overvalued given its current financial metrics, including a Price to Book Value of 1.48 and an EV to Sales ratio of 0.84, which, while not excessively high, do not compensate for the negative earnings and returns. Additionally, the company's ROE stands at -5.41%, reflecting ongoing losses.<BR><BR>In comparison to its peers, Keros Therapeutics, Inc. has a P/E ratio of 33.47, indicating a more favorable valuation, while REGENXBIO, Inc. is also considered risky with a P/E of -2.73. The stock has shown strong short-term performance, with a 1-week return of 8.76% compared to the S&P 500's 1.05%, but it has significantly underperformed over longer periods, such as a 5-year return of -58.16% versus the S&P 500's 96.61%. This disparity reinforces the notion that Arcturus Therapeutics is currently overvalued.

Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?

As of October 24, 2025, Arcturus Therapeutics has a mildly bullish technical trend, supported by daily moving averages and a weekly KST signal, but tempered by bearish weekly and monthly Bollinger Bands and mixed MACD signals.

As of 24 October 2025, the technical trend for Arcturus Therapeutics Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, suggesting some short-term strength. However, both the weekly and monthly Bollinger Bands are bearish, which adds caution. The KST shows a bullish signal on the weekly but bearish on the monthly, further contributing to the mixed outlook. Overall, the technical stance is mildly bullish, but the strength is tempered by bearish indicators in the Bollinger Bands and mixed MACD signals. Multi-period return data is not available for comparison with the S&P 500.